Evolocumab safely drops LDL cholesterol well below statin-only baseline, study suggests
Monday, March 31, 2014 - 14:01
in Health & Medicine
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to new data.